Patent · US Active

Androgen receptor-dependent gene expression control

US8680157B2 · kind B2 · utility

1Cited by

1References

11Claims

0Family size

Assignee

UNIVERSITAETSKLINIKUM FREIBURG · DE

Inventors

Roland Schuele · Kenzingen, DE
Eric Metzger · Neuf-Brisach, FR

Key dates

Filing date	Feb 16, 2006
Grant date	Mar 25, 2014
Priority date	—
Expiry date	Oct 30, 2028

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to assay systems allowing to test LSD1 inhibitors for their ability to inhibit LSD1 function.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.